Multidrug Resistant Tuberculosis Clinical Trial
— SMARTTOfficial title:
Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial
The primary aim of this pragmatic trial is to determine the effectiveness of a Whole Genome Sequencing (WGS) Drug Sensitivity Testing (DST) strategy to guide individualised treatment of rifampicin resistant tuberculosis (RR-TB) patients. The primary objective is to determine the effectiveness of this WGS DST strategy in patients diagnosed with RR-TB. We will additionally perform an exploratory health economics evaluation of both arms, and will determine the feasibility of the WGS DST strategy.
Status | Recruiting |
Enrollment | 248 |
Est. completion date | January 2025 |
Est. primary completion date | December 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosed with RR-TB - Diagnosed with pulmonary TB (PTB) or PTB plus extra-pulmonary TB (EPTB) - =18 years of age - Able to sign informed consent - Not on TB treatment at time of enrolment Exclusion Criteria: - Patients diagnosed EPTB without pulmonary involvement - Patients with TB Meningitis or TB of the bone. - Has any condition that, in the opinion of the investigator or physician, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, interfere with achieving the study objectives or compromise patient safety. |
Country | Name | City | State |
---|---|---|---|
South Africa | Free State Department of Health Clinics | Bloemfontein | Free State |
Lead Sponsor | Collaborator |
---|---|
Universiteit Antwerpen | Aurum Institute, Free State Department of Health, University of Stellenbosch, University of the Free State |
South Africa,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Effectiveness of a WGS DST strategy for individualisation of RR-TB treatment | The effectiveness will be determined by the rate of change in time to positivity (TTP) over 6 months in the Mycobacterial Growth Indicator Tuber (MGIT) system [time from: Day 0 to Week 24].
The effectiveness of the WGS DST strategy will be determined by the rate of change in TTP in liquid media MGIT cultures of sputum samples collected during the first 6 months of treatment. The TTP will be used to determine the change in mycobacterial load using a non-linear mixed effect time-to-event model that provides a longitudinal representation of mycobacterial load (measured as TTP in MGIT) at weeks 2, 3, 4, 5, 6, 7, 8, 12, 16, 20 and 24 |
Day 0 to month 6 (6 months) | |
Secondary | Health economic evaluation of a WGS DST strategy for individualization of RR-TB treatment | The difference in total cost over the entire treatment period from a patients and health system perspective between a WGS strategy and SOC strategy will be assessed by comparing costing data collected at month 1 of treatment, month 6 of treatment and at the end of treatment. | Start of treatment to end of treatment (which may vary from 6 months to over 11 months) | |
Secondary | Impact of WGS strategy for individualisation of RR-TB treatment on Health related Quality of Life (HRQOL) | The difference in changes in health relates quality fo life will be assessed by comparing the change in HRQOL over time between patients randomised to the WGS and SOC strategies for individualisation of RR-TB treatment, using results of the EQ-5D-5L questionnaire collected at baseline, month 1, 2, 3, 4, 5, 6 and end of treatment. | Start of treatment to end of treatment (which may vary from 6 months to over 11 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02496572 -
Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan
|
Phase 3 | |
Completed |
NCT03942354 -
Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
|
||
Completed |
NCT02454205 -
An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05081401 -
Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)
|
||
Completed |
NCT01856634 -
Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis
|
Phase 1 | |
Active, not recruiting |
NCT03867136 -
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)
|
Phase 4 | |
Not yet recruiting |
NCT04484129 -
MDR-TB Close Contacts Tracing in China (TCCT Study)
|
||
Completed |
NCT00727844 -
Linezolid to Treat Extensively-Drug Resistant Tuberculosis
|
Phase 2 | |
Completed |
NCT01859923 -
A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)
|
Phase 2 | |
Active, not recruiting |
NCT04421495 -
Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
|
Phase 4 | |
Active, not recruiting |
NCT04717908 -
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS
|
N/A | |
Not yet recruiting |
NCT03604848 -
NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB
|
N/A | |
Recruiting |
NCT02120638 -
Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide
|
Phase 3 | |
Recruiting |
NCT05534750 -
Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)
|
Phase 2 |